---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211964"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:59:05.952098+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Janux Q1 2026 net loss $24.4M; cash $956.4M; discontinues JANX008, initiates JANX014

## Summary
- Net loss of $24.4M for Q1 2026 vs $23.5M YoY; cash and investments at $956.4M.
- Discontinued JANX008 (EGFR-TRACTr) development after Phase 1a; resources redirected.
- Initiated clinical evaluation of JANX014 (PSMA-TRACTr); JANX007 combination with darolutamide enrolling.
- BMS collaboration milestone triggered $35M payment upon development candidate nomination.
- Appointed William Go, M.D., Ph.D. as Chief Medical Officer.

## SEC filing metadata
- accession: 0001193125-26-211964
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000119312526211964/0001193125-26-211964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000119312526211964/janx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211964
- JSON: https://secwatch.observer/filing/0001193125-26-211964.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211964.txt

## Source-grounded claims
- claim_id: 06085aaff9ca5707f8435b7d841f5693d4e2a53c
  claim: Janux Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $24.4 million for the quarter ended March 31, 2026.
  evidence_excerpt: Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000119312526211964/0001193125-26-211964-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.